Immunohistochemistry was used to measure p53 expression, which was then linked with clinicopathological features like tumour size, histological grade, lymph node status, lymphovascular invasion, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, Ki-67 proliferation index, and molecular subtype. This evidence concerns the gene TP53 and neoplasm.